- Home
- NPCE vs CRVS Comparison
NPCE vs CRVS Comparison
Compare NPCE & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- CRVS
- Stock Information
- Founded
- NPCE 1997
- CRVS 2014
- Country
- NPCE United States
- CRVS United States
- Employees
- NPCE N/A
- CRVS N/A
- Industry
- NPCE Medical Specialities
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- NPCE Health Care
- CRVS Health Care
- Exchange
- NPCE Nasdaq
- CRVS Nasdaq
- Market Cap
- NPCE 292.9M
- CRVS 305.4M
- IPO Year
- NPCE 2021
- CRVS 2016
- Fundamental
- Price
- NPCE $9.15
- CRVS $5.75
- Analyst Decision
- NPCE Strong Buy
- CRVS Strong Buy
- Analyst Count
- NPCE 6
- CRVS 4
- Target Price
- NPCE $16.67
- CRVS $15.00
- AVG Volume (30 Days)
- NPCE 205.3K
- CRVS 518.7K
- Earning Date
- NPCE 08-12-2025
- CRVS 08-07-2025
- Dividend Yield
- NPCE N/A
- CRVS N/A
- EPS Growth
- NPCE N/A
- CRVS N/A
- EPS
- NPCE N/A
- CRVS N/A
- Revenue
- NPCE $88,570,000.00
- CRVS N/A
- Revenue This Year
- NPCE $22.13
- CRVS N/A
- Revenue Next Year
- NPCE $6.07
- CRVS N/A
- P/E Ratio
- NPCE N/A
- CRVS N/A
- Revenue Growth
- NPCE 23.32
- CRVS N/A
- 52 Week Low
- NPCE $5.45
- CRVS $2.54
- 52 Week High
- NPCE $18.98
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- NPCE 51.74
- CRVS 65.10
- Support Level
- NPCE $8.61
- CRVS $5.28
- Resistance Level
- NPCE $8.99
- CRVS $5.64
- Average True Range (ATR)
- NPCE 0.53
- CRVS 0.30
- MACD
- NPCE 0.11
- CRVS 0.03
- Stochastic Oscillator
- NPCE 75.00
- CRVS 77.70
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).